ACR Highlights Imaging Payment Changes in HOPPS Final Rule
ACR outlines key radiology updates in CMS 2026 HOPPS final rule, including payment changes and quality reporting updates effective Jan. 1.
Read moreThe National Cancer Institute (NCI) recently announced two new resources for cancer researchers.
The first, the NCI Fiscal Year 2026 (FY26) Annual Plan & Professional Judgment Budget Proposal: Leading Progress Against Cancer, presents NCI’s assessment of the optimal funding needed to fully capitalize on scientific opportunities and advance cancer research. The annual plan highlights four areas of opportunity: Tackling the Emergence of Early-Onset Cancers in Young Adults, Approaching Cancer as a Disease that Affects the Entire Body, Alleviating Financial Toxicity for Cancer Survivors and Caregivers and Expanding the Utility of Cancer-Targeting Vaccines.
The second resource is the NCI Cancer Research Data Commons’ (CRDC) new Clinical and Translational Data Commons (CTDC). Designed to enhance access to clinical and translational data from NCI-funded initiatives, the CTDC is a pivotal resource in accelerating cancer discovery. The goals of the CTDC are to advance cancer research and accelerate the development of innovative therapies by improving access to data from NCI-sponsored clinical studies, including genomic panel assay and clinical data. The CTDC’s inaugural data set comes from the Cancer Moonshotâ Biobank (CMB), a study collecting clinical data and biospecimens shared by participants throughout their standard of care treatments at participating US medical institutions.
Key features of the CTDC include:
NCI will host a live demonstration of CTDC’s capabilities in the September data science seminar series Sept. 25 at 11am ET.
For more information, contact Katie Grady, American College of Radiology® Government Affairs Director.
ACR Highlights Imaging Payment Changes in HOPPS Final Rule
ACR outlines key radiology updates in CMS 2026 HOPPS final rule, including payment changes and quality reporting updates effective Jan. 1.
Read moreACR Provides Input to FDA on AI Measurement and Evaluation
ACR submitted comments to FDA on real-world AI device performance, stressing safety, governance, and continuous monitoring.
Read moreRadiologyâs Fight Against Prior Authorization Delays
ACR is leading national efforts to make prior authorization more efficient and clinically appropriate while reducing the administrative burden and supporting national legislation.
Read more